Zhen-Huan Hu

List of Publications by Year
in descending order

48	2,061	331670 21	243625 44
papers	citations	h-index	g-index

49	49	49	3351
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. New England Journal of Medicine, 2017, 376, 536-547.	27.0	586
2	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Advances, 2020, 4, 5414-5424.	5.2	263
3	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood, 2014, 124, 1372-1377.	1.4	178
4	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2014, 20, 89-97.	2.0	130
5	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood, 2019, 134, 764-764.	1.4	77
6	Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood, 2019, 134, 766-766.	1.4	70
7	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
8	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871.	1.6	61
9	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. Blood, 2020, 136, 137-139.	1.4	51
10	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biology of Blood and Marrow Transplantation, 2016, 22, 932-940.	2.0	43
11	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biology of Blood and Marrow Transplantation, 2016, 22, 744-751.	2.0	41
12	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 767-775.	2.0	41
13	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 951-959.	2.0	37
14	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	5.2	35
15	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257.	2.0	33
16	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	7.1	32
17	Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABLâ€“negative MPN in blast phase. Blood Advances, 2020, 4, 5562-5573.	5.2	28
18	Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry. Blood, 2019, 134, 2619-2619.	1.4	28

#	Article	IF	Citations
19	The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood, 2021, 138, 898-911.	1.4	27
20	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1056-1064.	2.0	26
21	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood, 2020, 136, 3070-3081.	1.4	25
22	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
23	Direct adjusted survival and cumulative incidence curves for observational studies. Bone Marrow Transplantation, 2020, 55, 538-543.	2.4	17
24	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 971-979.	2.0	16
25	Comparison of outcomes of HCT in blast phase of BCR-ABL1â˜ MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	5.2	14
26	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
27	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biology of Blood and Marrow Transplantation, 2020, 26, 1137-1143.	2.0	13
28	Role of survivor bias in pancreatic cancer case-control studies. Annals of Epidemiology, 2016, 26, 50-56.	1.9	11
29	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
30	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood, 2021, 138, 429-429.	1.4	9
31	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. Blood, 2021, 138, 530-530.	1.4	9
32	Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood, 2021, 138, 428-428.	1.4	9
33	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, S30-S31.	2.0	8
34	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia and Lymphoma, 2020, 61, 2811-2820.	1.3	7
35	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 581-586.	2.0	5
36	A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation. Bone Marrow Transplantation, 2022, 57, 6-10.	2.4	5

#	Article	IF	Citations
37	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 3880-3880.	1.4	4
38	Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm. Biology of Blood and Marrow Transplantation, 2020, 26, S12.	2.0	3
39	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee. Blood, 2018, 132, 206-206.	1.4	3
40	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
41	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report. Blood, 2017, 130, 667-667.	1.4	2
42	Impact of Race on Graft-Versus-Host Disease Rates after HLA-Matched Sibling Bone Marrow or Peripheral Blood Hematopoietic Cell Transplantation: Comparison of North American Caucasian Versus Japanese Populations. Biology of Blood and Marrow Transplantation, 2015, 21, S34-S35.	2.0	1
43	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTRÂ®) Study. Blood, 2015, 126, 2003-2003.	1.4	1
44	Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis. Blood, 2020, 136, 43-44.	1.4	1
45	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) with Antecedent History of Philadelphia-Negative Myeloproliferative Neoplasm with De Novo AML and with AML Arising from Myelodysplastic Syndrome: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biology of Blood and Marrow Transplantation, 2019, 25, S107.	2.0	0
46	A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Blood, 2015, 126, 64-64.	1.4	0
47	Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 2256-2256.	1.4	0
48	Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation. Blood, 2018, 132, 704-704.	1.4	0